Long-term effect of intravenous thrombolytic therapy in acute stroke: Responder analysis versus uniform analysis of excellent outcome

Cerebrovascular Diseases

Volumn 20, Issue 6, 2005, Pages 470-474

  Thomassen, Lars ^a   Waje Andreassen, Ulrike ^a   Naess, Halvor ^a   Elvik, May Karin ^a   Russell, David ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Responder analysis; Stroke; Thrombolysis

Indexed keywords

FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; HEMATOMA; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PONS; PRIORITY JOURNAL; RANKIN SCALE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CEREBROVASCULAR ACCIDENT; DATA INTERPRETATION, STATISTICAL; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; THROMBOLYTIC THERAPY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 27944451769     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089334     Document Type: Article

References (19)

1. Albers GW, Bates VE, Clark WM, et al: Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145-1150.
2. Buchan AM, Barber PA, Newcommon N, et al: Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness. Neurology 2000;54:679-684.
3. Chiu D, Krieger D, Villar-Cordova C, et al: Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998;29:18-22.
4. Grond M, Stenzel C, Schmulling S, et al: Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998;29:1544-1549.
5. Katzan IL, Hammer MD, Furlan AJ, et al: Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 2003;34:799-800.
6. Lindsberg PJ, Soinne L, Roine RO, et al: Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke 2003;34: 1443-1449.
7. NINDS: NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
8. Thomassen L, Waje-Andreassen U, Morsund AH, et al: Thrombolytic therapy in acute ischaemic stroke. Cerebrovasc Dis 2002;13:163-167.
9. Hacke W, Kaste M, Fieschi C, et al: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-1251.
10. Hacke W, Kaste M, Fieschi C, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274: 1017-1025.
11. Kwiatkowski TG, Libman RB, Frankel M, et al: Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999;340: 1781-1787.
12. Schenkel J, Weimar C, Knoll T, et al: R1 - systemic thrombolysis in German stroke units - the experience from the German Stroke Data Bank. J Neurol 2003;250:320-324.
13. Schmulling S, Grond M, Rudolf J, et al: One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke 2000;31: 1552-1554.
14. Adams HP Jr, Leclerc JR, Bluhmki E, et al: Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovasc Dis 2004;18:124-129.
15. Hacke W, Kaste M, Bogousslavsky J, et al: European Stroke Initiative Recommendations for Stroke Management - update 2003. Cerebrovasc Dis 2003;16:311-337.
16. Wilson JT, Hareendran A, Grant M, et al: Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke 2002;33: 2243-2246.
17. Hacke W: Therapeutic benefit of abciximab in acute ischemic stroke as measured by modified Rankin Scale (mRS) responder analysis. Cerebrovasc Dis 2003;16:113.
18. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators: Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005;36:880-890.
19. Hacke W, Donnan G, Fieschi C, et al: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363: 768-774.